Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Dosage 52

Dosage Compounding Labelling FDA 52

pharmaphorum

JUNE 14, 2022

The approval comes despite scrutiny of the safety of the JAK inhibitor class by the FDA, with the risk of heart-related issues leading to warnings being applied to the labels of Olumiant and other drugs in the class including Pfizer’s Xeljanz (tofacitinib) and AbbVie’s Rinvoq (upadacitinib).

Labelling 98

Labelling FDA Insurance 98

pharmaphorum

OCTOBER 26, 2022

billion a 25% gain in the prior year and fuelled in part by extensions to its label to include other progressive ILDs. Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable.

Labelling 98

Labelling FDA 98

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Specifically, across all the major classes there are significant developments, label updates, and biosimilar launches that are driving their growth. billion in 2029, although its sales growth is likely to continue beyond 2029.

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

FEBRUARY 23, 2022

It also includes data from a long-term, open-label study that focused on the safety and tolerability of the drug over 26 weeks. Analysts at GlobalData are predicting peak sales of $383 million for the drug in 2029. Vraylar is now one of AbbVie’s fastest-growing products with sales expected to reach around $2.2

Labelling 52

Labelling FDA 52

pharmaphorum

NOVEMBER 24, 2022

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide. Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments.

Labelling 52

Labelling Hospitals 52

The Checkup by Singlecare

DECEMBER 6, 2023

Xifaxan may be prescribed off-label for other intestine problems, including small intestinal bacterial overgrowth ( SIBO ) or C. The earliest generic rifaximin may be put on the market is 2029. Overt hepatic encephalopathy is a condition in which liver disease causes brain dysfunction because of the buildup of toxins in the blood.

Insurance 52

Insurance Dosage Labelling FDA 52